Header Logo

Connection

JOHN KIRKWOOD to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Neoplasm Staging.
JOHN KIRKWOOD
Connection Strength
4.328
Neoplasm Staging
  1. Cutaneous Melanoma: A Review. JAMA. 2025 Dec 16; 334(23):2113-2125.
    View in: PubMed
    Score: 0.179
  2. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
    View in: PubMed
    Score: 0.170
  3. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
    View in: PubMed
    Score: 0.158
  4. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 11; 29(11):2835-2843.
    View in: PubMed
    Score: 0.154
  5. State of Melanoma: An Historic Overview of a Field in Transition. Hematol Oncol Clin North Am. 2021 02; 35(1):1-27.
    View in: PubMed
    Score: 0.125
  6. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
    View in: PubMed
    Score: 0.110
  7. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
    View in: PubMed
    Score: 0.109
  8. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
    View in: PubMed
    Score: 0.104
  9. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
    View in: PubMed
    Score: 0.102
  10. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
    View in: PubMed
    Score: 0.101
  11. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.100
  12. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017 Jul 15; 123(14):2688-2697.
    View in: PubMed
    Score: 0.098
  13. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
    View in: PubMed
    Score: 0.097
  14. Downstream consequences of melanoma screening in a community practice setting: First results. Cancer. 2016 Oct 15; 122(20):3152-3156.
    View in: PubMed
    Score: 0.093
  15. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
    View in: PubMed
    Score: 0.088
  16. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
    View in: PubMed
    Score: 0.079
  17. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013 Aug 01; 19(15):4228-38.
    View in: PubMed
    Score: 0.075
  18. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
    View in: PubMed
    Score: 0.072
  19. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012 Nov-Dec; 35(9):702-10.
    View in: PubMed
    Score: 0.072
  20. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
    View in: PubMed
    Score: 0.068
  21. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41.
    View in: PubMed
    Score: 0.068
  22. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):555-67.
    View in: PubMed
    Score: 0.067
  23. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol. 2009 Oct; 36(5):419-31.
    View in: PubMed
    Score: 0.058
  24. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
    View in: PubMed
    Score: 0.056
  25. Highlights from the perspectives in melanoma XII conference. Pigment Cell Melanoma Res. 2009 Apr; 22(2):156-65.
    View in: PubMed
    Score: 0.056
  26. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
    View in: PubMed
    Score: 0.056
  27. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
    View in: PubMed
    Score: 0.051
  28. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
    View in: PubMed
    Score: 0.050
  29. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.045
  30. Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005 Dec 01; 23(34):8559-63.
    View in: PubMed
    Score: 0.044
  31. Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
    View in: PubMed
    Score: 0.043
  32. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
    View in: PubMed
    Score: 0.043
  33. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 11 07; 391(18):1709-1720.
    View in: PubMed
    Score: 0.040
  34. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
    View in: PubMed
    Score: 0.040
  35. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.040
  36. Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts. Cancer Med. 2023 12; 12(24):22103-22108.
    View in: PubMed
    Score: 0.039
  37. Medical management of melanoma. Surg Clin North Am. 2003 Apr; 83(2):283-322, viii.
    View in: PubMed
    Score: 0.037
  38. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
    View in: PubMed
    Score: 0.036
  39. Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited. Arch Dermatol. 2003 Jan; 139(1):99; author reply 99-100.
    View in: PubMed
    Score: 0.036
  40. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.
    View in: PubMed
    Score: 0.036
  41. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova). 2003; 13(2):127-40; quiz 187-8.
    View in: PubMed
    Score: 0.036
  42. Patient-reported tolerability of adjuvant ipilimumab (3 or 10?mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan; 32(1):183-196.
    View in: PubMed
    Score: 0.036
  43. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 11 10; 40(32):3741-3749.
    View in: PubMed
    Score: 0.035
  44. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
    View in: PubMed
    Score: 0.035
  45. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol. 2022 10; 87(4):906-908.
    View in: PubMed
    Score: 0.035
  46. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002 Apr 15; 20(8):2053-7.
    View in: PubMed
    Score: 0.035
  47. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001 Sep; 137(9):1217-24.
    View in: PubMed
    Score: 0.033
  48. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
    View in: PubMed
    Score: 0.033
  49. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 Aug 15; 19(16):3635-48.
    View in: PubMed
    Score: 0.033
  50. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.
    View in: PubMed
    Score: 0.032
  51. Neoadjuvant Pembrolizumab and High-Dose IFNa-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021 08 01; 27(15):4195-4204.
    View in: PubMed
    Score: 0.032
  52. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
    View in: PubMed
    Score: 0.031
  53. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.
    View in: PubMed
    Score: 0.031
  54. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91.
    View in: PubMed
    Score: 0.030
  55. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.030
  56. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep; 17(9):2745-51.
    View in: PubMed
    Score: 0.029
  57. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 08; 83(2):587-590.
    View in: PubMed
    Score: 0.028
  58. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
    View in: PubMed
    Score: 0.028
  59. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
    View in: PubMed
    Score: 0.028
  60. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998 Aug; 12(4):823-33.
    View in: PubMed
    Score: 0.027
  61. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.027
  62. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
    View in: PubMed
    Score: 0.027
  63. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
    View in: PubMed
    Score: 0.026
  64. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 02 01; 36(4):399-413.
    View in: PubMed
    Score: 0.026
  65. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
    View in: PubMed
    Score: 0.025
  66. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
    View in: PubMed
    Score: 0.025
  67. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
    View in: PubMed
    Score: 0.025
  68. The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
    View in: PubMed
    Score: 0.024
  69. Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
    View in: PubMed
    Score: 0.024
  70. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
    View in: PubMed
    Score: 0.022
  71. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
    View in: PubMed
    Score: 0.020
  72. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
    View in: PubMed
    Score: 0.020
  73. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.020
  74. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
    View in: PubMed
    Score: 0.019
  75. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
    View in: PubMed
    Score: 0.018
  76. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
    View in: PubMed
    Score: 0.018
  77. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012 Feb 15; 18(4):1129-37.
    View in: PubMed
    Score: 0.017
  78. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med. 2011 May 26; 9:78.
    View in: PubMed
    Score: 0.016
  79. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010 Aug 16; 8:76.
    View in: PubMed
    Score: 0.015
  80. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.015
  81. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
    View in: PubMed
    Score: 0.015
  82. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
    View in: PubMed
    Score: 0.015
  83. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68.
    View in: PubMed
    Score: 0.014
  84. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
    View in: PubMed
    Score: 0.013
  85. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008 Feb 20; 26(6):955-62.
    View in: PubMed
    Score: 0.013
  86. Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
    View in: PubMed
    Score: 0.013
  87. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
    View in: PubMed
    Score: 0.012
  88. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene. 2007 Jun 21; 26(29):4216-25.
    View in: PubMed
    Score: 0.012
  89. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007; 54:241-7.
    View in: PubMed
    Score: 0.012
  90. Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005 Dec 15; 104(12):2784-91.
    View in: PubMed
    Score: 0.011
  91. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.
    View in: PubMed
    Score: 0.008
  92. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.007
  93. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998 Sep 01; 42(2):269-76.
    View in: PubMed
    Score: 0.007
  94. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3.
    View in: PubMed
    Score: 0.006
  95. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.